title: Case of relentless chronic phase of chronic myeloid leukaemia.
abstract: Initial treatment of chronic phase chronic myeloid leukaemia is straightforward in today's era of tyrosine kinase inhibitors. However, managing refractory cases remain a major challenge due to the multiple factors that can influence decision-making, including medication tolerance, disease burden, mutation status, comorbidities, availability of donor, and fitness for an ablative conditioning. We report a male patient presenting with chronic phase chronic myeloid leukaemia who was treated with 5 different tyrosine kinase inhibitors either due to intolerance and/or failed response. He subsequently received 2 haploidentical haematopoietic stem cells transplants before achieving complete remission. This case highlights various treatment options, need for vigilant disease monitoring, and the possibility of complete positive response even after many lines of therapy failure.
authors.affiliation: Department of Internal Medicine, University of Arizona Medical Center-University Campus, Tucson, Arizona, USA.
authors.forename: Onyee
authors.initials: O
authors.lastname: Chan
authors.affiliation: Department of Pathology, University of Arizona Medical Center-University Campus, Tucson, Arizona, USA.
authors.forename: Hao
authors.initials: H
authors.lastname: Chen
authors.affiliation: Department of Hematology Oncology, University of Arizona Medical Center-University Campus, Tucson, Arizona, USA.
authors.forename: Ravitharan
authors.initials: R
authors.lastname: Krishnadasan
authors.affiliation: Department of Hematology Oncology, University of Arizona Medical Center-University Campus, Tucson, Arizona, USA.
authors.forename: Faiz
authors.initials: F
authors.lastname: Anwer
mesh_terms: D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012074:Remission Induction; D016879:Salvage Therapy; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous / Q000379:methods*
chemical_list: D047428:Protein Kinase Inhibitors